

For Professional Use Only

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit Instruction Manual

AmpliSens[®]



Ecoli s.r.o., Studenohorska 12 841 03 Bratislava 47 Slovak Republic Tel.: +421 2 6478 9336 Fax: +421 2 6478 9040



Federal Budget Institute of Science "Central Research Institute for Epidemiology" 3A Novogireevskaya Street Moscow 111123 Russia

TABLE OF CONTENTS

| 1. INTENDED USE | 3 |
|-------------------------------|----|
| 2. PRINCIPLE OF PCR DETECTION | 3 |
| 3. CONTENT | 4 |
| 4. ADDITIONAL REQUIREMENTS | 5 |
| 5. GENERAL PRECAUTIONS | 6 |
| 6. SAMPLING AND HANDLING | |
| 7. WORKING CONDITIONS | |
| 8. PROTOCOL | |
| 9. DATA ANALYSIS | 11 |
| 10. TROUBLESHOOTING | 12 |
| 11. TRANSPORTATION | |
| 12. STABILITY AND STORAGE | |
| 13. SPECIFICATIONS | |
| 14. REFERENCES | |
| 15. QUALITY CONTROL | 13 |
| 16. KEY TO SYMBOLS USED | 14 |
| | |

1. INTENDED USE

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit is an in vitro nucleic acid amplification test for qualitative detection of *Pneumocystis jirovecii (carinii)* in the clinical material (bronchoalveolar lavage, sputum, biopsy material, throat washes and swabs) by using real-time hybridization-fluorescence detection.



The results of PCR analysis are taken into account in complex diagnostics of disease.

2. PRINCIPLE OF PCR DETECTION

Pneumocystis species microorganisms are unicellular fungi that infect respiratory system of mammalians including human. Pneumocystis carinii was the only species that belonged to Pneumocystis genus for a long time. According to modern classification microorganisms dwelling in human organs unite in Pneumocystis jirovecii (Pneumocystis carinii earlier) species.

Microorganisms of pneumocystis genius cause group of diseases called pneumocystosis. Pneumocystosis is associated with lethal outcomes in 65-85 % of AIDS suffering patients and considered most significant AIDS markers. Pneumocystosis can be divided into four types: asymptomatic infections, pneumonia of children, pneumonia associated with depressed immunity, and extrapulmonary infections. Due to low virulence of the pathogen, the infection rarely comes out of lungs. However, development of extrapulmonary infections is possible if the infection spreads from lungs to other organs, including lymph nodes, spleen, bone marrow, liver, kidneys, heart, brain, pancreas, etc. Diagnosis of such illnesses happens accidentally, and as a rule, cannot be clinically confirmed. Extrapulmonary pneumocystosis develops in lymph nodes, spleen, bone marrow, gastrointestinal tract, eyes, thyroid gland, adrenals, and kidneys.

Serologic studies results suggest prevalence of pneumosistis in adults. Initial infection occurs in childhood and 94 % of kids have pneumocystis antibodies at four years old. Pneumocystosis cannot be detected by direct method in adults.

Most likely pneumocystis are transmitted with respiratory secretions, however, infective form of microorganism is unknown.

Carriage of pneumocystis in organism was not reliable verified. This issue remains controversial so far. Therefore, people belonging to group of high risk of opportunistic infections development should be tested for pneumocystis. Diagnosis should base on complex examination data including clinical, X-ray, and laboratory check. Polymerase chain

reaction is a very sensitive method that allows detection of single copies of pathogen DNA in bronchoalveolar lavage, sputum, throat washes and swabs, respiratory biopsy material, blood, etc. Consequently, for pneumocystis pneumonia diagnostics this method should be used as supporting, but not main.

Method of detection of *Pneumocystis jirovecii* DNA from clinical material, containing cells, is based on:

- 1. Extraction of total DNA from cells suspension (whole blood, leucocytes, homogenized biopsy material).
- Simultaneous real-time amplification of specific region of mitochondrial DNA large subunit and specific region of human β-globin gene, used as endogenous internal control.

Result of *Pneumocystis jirovecii* DNA amplification is registered on JOE/HEX/Yellow fluorescence channel, result of Internal control DNA amplification is registered on FAM/Green channel. DNA-target selected as endogenous internal control is the fragment of human genome and must be present in a sample of DNA from whole blood, leucocytes and biopsy material in sufficient quantity equivalent to that of cells in the sample (no less than 20000 genomes per sample or DNA from 10000 cells). In case of irrelevant storage of clinical sample cells destruction and DNA degradation can occur. Bad DNA extraction from clinical material can lead to significant loss of DNA or presence of inhibitors in purified DNA sample. So, endogenous internal control allows not only to check PCR-analysis steps, but also to assess sampling adequacy and clinical material safety.

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit uses "hot-start", which greatly reduces frequency of nonspecifically primed reactions. "Hot-start" is guaranteed by using of chemically modified polymerase (TaqF). Chemically modified polymerase (TaqF) is activated by heating at 95 °C for 15 min.

3. CONTENT

AmpliSens[®] Pneumocystis jirovecii (carinii)-FRT PCR kit is produced in 1 form:

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit variant FRT-50 F, **REF** R-F2(RG,iQ,Mx)-CE.

AmpliSens[®] Pneumocystis jirovecii (carinii)-FRT PCR kit variant FRT-50 F includes:

| Reagent | Description | Volume (ml) | Amount |
|---|------------------------|----------------|---------|
| PCR-mix-1-FRT <i>P.jirovecii /</i> Glob | colorless clear liquid | 0.42 | 1 tube |
| PCR-buffer-FRT | colorless clear liquid | 0.3 | 2 tubes |
| Polymerase (TaqF) | colorless clear liquid | 0.02 | 2 tubes |
| Positive Control DNA <i>P.jirovecii</i> and human DNA (C+ _{P.jirovecii}) | colorless clear liquid | 0.1 | 1 tube |
| DNA-buffer | colorless clear liquid | 0.5 | 1 tube |

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit variant FRT-50 F is intended for 55 reactions (including controls).

4. ADDITIONAL REQUIREMENTS

- DNA isolation kit.
- Disposable powder-free gloves and laboratory coat.
- Pipettes (adjustable).
- Sterile pipette tips with aerosol barriers (up to 200 µl).
- Tube racks.
- Vortex mixer.
- Desktop centrifuge with rotor for 2 ml reaction tubes.
- PCR box.
- Personal thermocyclers (for example, Rotor-Gene 3000 or Rotor-Gene 6000 (Corbett Research, Australia); iQ5 or iQ iCycler (Bio-Rad, USA), Mx3000P (Stratagene, USA) or equivalent).
- <u>Rotor-Gene</u>: disposable polypropylene undomed and unsrtipe 0.2 ml microtubes for PCR (for instance, Axygen, USA) for 36-well rotor or 0.1-ml microtubes (Corbett Research, Australia) for 72-well rotor.

<u>iQ5, iQ iCycler:</u> disposable polypropylene domed 0.2-ml microtubes for PCR (for instance, Axygen, USA), stripe domed tubes or 96-wells plate for PCR equipped with heat-proof optical transparent films (Bio-Rad, USA).

<u>Mx3000P</u>: disposable polypropylene domed and stripe/unsrtipe 0.2-ml microtubes for PCR (for instance, Axygen, USA) for 36-well rotor or plate for PCR equipped with heat-proof optical transparent films (Bio-Rad, USA).

- Refrigerator for 2–8 °C.
- Deep-freezer for ≤ -16 °C.
- Waste bin for used tips.

5. GENERAL PRECAUTIONS

The user should always pay attention to the following:

- Use sterile pipette tips with aerosol barriers and use new tip for every procedure.
- Store and handle amplicons away from all other reagents.
- Thaw all components thoroughly at room temperature before starting detection.
- When thawed, mix the components and centrifuge briefly.
- Use disposable gloves, laboratory coats, protect eyes while samples and reagents handling. Thoroughly wash hands afterward.
- Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas.
- Do not use a kit after its expiration date.
- Dispose of all samples and unused reagents in compliance with local authorities requirements.
- Samples should be considered potentially infectious and handled in a biological cabinet in accordance with appropriate biosafety practices.
- Clean and disinfect all sample or reagent spills using a disinfectant such as 0.5% sodium hypochlorite, or other suitable disinfectant.
- Avoid contact with the skin, eyes and mucosa. If skin, eyes and mucosa contact immediately flush with water, seek medical attention.
- Material Safety Data Sheets (MSDS) are available on request.
- Use of this product should be limited to personnel trained in the techniques of DNA amplification.
- The laboratory process must be one directional, it should begin in the Extraction Area move to the Amplification and Detection Area. Do not return samples, equipment and reagents to the area in which the previous step was performed.



Some components of this kit contain sodium azide as a preservative. Do not use metal tubing for reagent transfer.

6. SAMPLING AND HANDLING



Obtaining samples of biological materials for PCR-analysis, transportation and storage are described in manufacturer's handbook [1]. It is recommended that this handbook is read before starting work.

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit is intended for analysis of DNA extracted with DNA isolation kits from:

- bronchoalveolar lavage;
- sputum;
- biopsy material;
- throat washes and swabs.
- 6.1. Bronchoalveolar lavage sample should be placed into sterile disposable tube or container. Thoroughly resuspend the sample and transfer 1 ml of material into an Eppendorf tube using the tip with aerosol barrier. Centrifuge the tube for 10 min at 7000 g (8000-10000 rpm in 24-well centrifuge and 10000-13000 rpm in 12-well centrifuge). Carefully remove and discard the supernatant using a tip with aerosol barrier and leaving 200 µl of the liquid on the sediment. Resuspend the sample on vortex.
- 6.2. Sputum. Sputum is collected into a sterile disposable container after preliminary mouth rinsing with water. Add Mucolysin reagent REF 180 to sputum sample in ratio 5:1 (5 volume of Mucolysin per 1 volume of sputum) using graduation on a container. While sputum is liquefied (20-30 min) shake the container occasionally. Transfer 1 ml of the sample into an 1.5-ml Eppendorf tube using tip with aerosol barrier and centrifuge at 7000 g (8000–10000 rpm in 24-well centrifuge or 10000 13000 rpm in 12-well centrifuge) for 10 min. Remove and discard the supernatant using vacuum aspirator. Resuspend the pellet in 100 μl of PBS-buffer (or saline solution) and use for DNA extraction.
- 6.3. Biopsy material samples should be placed in a sterile disposable 1.5-ml tube with tightly sealed cups or container. For further examination place a sample in a sterile porcelain mortar. Add equal volume of saline solution or PBS buffer. Thoroughly homogenize the sample with a pestle. Transfer 100 µl of prepared suspension in a sterile tube for DNA extraction.
- 6.4. *Throat washes and swabs* are obtained by sterile probe and placed in a tube with transport media.



Only one freeze-thaw cycle of clinical material is allowed.

7. WORKING CONDITIONS

AmpliSens[®] Pneumocystis jirovecii (carinii)-FRT PCR kit should be used at 18–25 °C.

8. PROTOCOL

8.1. DNA Isolation

It is recommended to use the following nucleic acid extraction kits:

- DNA-sorb-B, **REF** K1-2-50-CE.
- RIBO-prep, REF K2-9-Et-50-CE.



Carry the DNA isolation according to the manufacturer's instructions.

8.2. Preparing the PCR

Total reaction volume - 25 µl, volume of DNA sample – 10 µl.

8.2.1 Preparing tubes for PCR

1. Preparation of **PCR-buffer-FRT** and **polymerase(TaqF**) mixture:

Add 0.02 ml of polymerase (TaqF) into the tube that contains 0.3 ml of PCR-buffer-

FRT and vortex carefully. Label the tube indicating the date of preparation. Use only

disposable tips with aerosol barrier.



Store prepared mix at the temperature between 2 and 8 °C for 3 month and use as needed.

If smaller amount of prepared mix is intended to be used within 3 month, reaction mix should be prepared in required volume in 15:1 ratio (for example, 150 µl of PCR-buffer-FRT and 10 µl of polymerase (TaqF)

- 2. Prepare required number of tubes or stripes for amplification of DNA from clinical and control samples, including two controls.
- 3. Add reagents in the tubes (refer to table 1).

Table 1

Methods of reagents addition in the tubes

| First method | Second method |
|--|--|
| Pipette 7 μl of PCR-mix-1-FRT <i>P.jirovecii</i> / Glob in each tube. Add above 8 μl of prepared mix of PCR-buffer-FRT and polymerase (TaqF). | Prepare reaction mix for required number of reactions. In a single tube add PCR-mix-1-FRT <i>P.jirovecii</i> / Glob and prepared mixture of PCR-buffer-FRT and polymerase (TaqF) calculating per 1 reaction: 7 μl of PCR-mix-1-FRT <i>P.jirovecii</i> / Glob; 8 μl of prepared mixture of PCR-buffer-FRT and polymerase (TaqF). When estimating reaction volume include three additional reactions: negative and positive controls and one extra reaction. Pipette 15 μl of prepared reaction mix in the microtubes. |

Table 2

Scheme of reaction mix preparation

The values are calculated including one extra reaction and two controls (positive and

| Number of samples to be analyzed | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| PCR-mix-1-FRT <i>P.jirovecii /</i> Glob (µl) | 42 | 49 | 56 | 63 | 70 | 77 | 84 | 91 | 98 | 105 | 112 | 119 | 126 | 133 | 140 |
| mix of PCR- buffer-FRT and polymerase (TaqF) (µl) | 48 | 56 | 64 | 72 | 80 | 88 | 96 | 104 | 112 | 120 | 128 | 136 | 144 | 152 | 160 |
| Number of samples to be analyzed | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 |
| PCR-mix-1-FRT P.jirovecii / Glob (µl) | 147 | 154 | 161 | 168 | 175 | 182 | 189 | 196 | 203 | 210 | 217 | 224 | 231 | 238 | 245 |
| mix of PCR- buffer-FRT and polymerase (TaqF) (µl) | 168 | 176 | 184 | 192 | 200 | 208 | 216 | 224 | 232 | 240 | 248 | 256 | 264 | 272 | 280 |

negative controls of amplification).

4. Using tips with aerosol barrier add **10 μl** of **DNA** obtained from clinical or control samples at the DNA extraction stage into microtubes or part of plate.



When adding DNA sample ensure that sorbent is not transferred into the tube with reaction mix.

5. Carry the control amplification reactions:

NCA - Add 10 µl of DNA-buffer to the tube labeled NCA (Negative Control of

REF R-F2(RG,iQ,Mx)-CE / VER 10.08.10–20.01.13 / Page 9 of 15

Amplification).

C+ - Add **10 μl** of **Positive Control DNA** *P.jirovecii* and human DNA in the tube labeled C+ (Positive Control of Amplification).

8.2.2. Amplification

8.2.2.1. Rotor-Gene 3000 or Rotor-Gene 6000

- 1. Program the Rotor-Gene according to manufacturer's manual and Guidelines [2].
- 2. Create a temperature profile on your Rotor-Gene instrument as follows:

Table 3

Programming of a thermocycler for Pneumocystis jirovecii DNA amplification

| Step | Temperature, °C | Time | Fluorescence detection | Repeats |
|---------|-----------------|--------|---------------------------|---------|
| Hold | 95 | 15 min | - | 1 |
| | 95 | 15 sec | - | |
| Cycling | 60 | 45 sec | FAM/Green, JOE/Yellow | 45 |

- 3. Fluorescence detection is on FAM/Green and JOE/Yellow fluorometer channels.
- 4. Make the adjustment of the fluorescence channel sensitivity according to Guidelines.

8.2.2.2. iQ5 or iQ iCycler

- 1. Program the iQ according to manufacturer's manual and Guidelines.
- 2. Create a temperature profile on your iQ instrument as follows:

Table 4

Programming of a thermocycler for Pneumocystis jirovecii DNA amplification

| Step | Temperature, °C | Time | Fluorescence detection | Repeats |
|---------|-----------------|--------|---------------------------|---------|
| Hold | 95 | 15 min | _ | 1 |
| Cycling | 95 | 20 sec | - | 45 |
| Cycling | 60 | 60 sec | FAM, HEX | 40 |

3. Fluorescence detection is on FAM and HEX fluorometer channels.

4. Make the adjustment of the fluorescence channel sensitivity according to Guidelines.

8.2.2.3. Mx3000P

- 1. Program the Mx3000P according to manufacturer's manual and Guidelines.
- 2. Create a temperature profile on your iQ instrument as follows:

Table 5

| Step | Temperature, °C | Time | Fluorescence detection | Repeats |
|---------|-----------------|--------|---------------------------|---------|
| Hold | 95 | 15 min | — | 1 |
| Cycling | 95 | 20 sec | _ | 45 |
| Cycling | 60 | 60 sec | FAM, HEX | 45 |

Programming of a thermocycler for Pneumocystis jirovecii DNA amplification

3. Fluorescence detection is on FAM and HEX fluorometer channels.

4. Make the adjustment of the fluorescence channel sensitivity according to Guidelines.

9. DATA ANALYSIS

Obtained data (curves of accumulation of fluorescent signals on two channels) are analyzed automatically by software of used devices for amplification and real-time hybridization-fluorescence detection.

Accumulation of β-globin gene DNA (Internal Control) amplification product is registered on FAM/Green channel; accumulation of *P.jirovecii* DNA (Positive Control) amplification product is registered on JOE/HEX/Yellow channel.

9.1. Results interpretation.

The results are interpreted by the software of Rotor-Gene 3000 or Rotor-Gene 6000, iQ5 or iQ iCycler or Mx3000P Instrument by the crossing (or not) of the fluorescence curve with the threshold line.

| Control | Stage for control | Ct channel FAM/Green | Ct channel JOE/Yellow/HEX | Interpretation |
|---------|-------------------|-------------------------|------------------------------|----------------|
| C- | DNA isolation | Neg | Neg | OK |
| NCA | Amplification | Neg | Neg | OK |
| C+ | Amplification | Pos (< Y*) | Pos (< X*) | OK |

Results for controls

- 1. The sample is considered to be positive for *Pneumocystis jirovecii* if its Ct value does not exceed Z* on JOE/Yellow/HEX channel. Fluorescence curve should cross the threshold line in the area of exponential fluorescence growth.
- 2. The sample is considered to be negative for *Pneumocystis jirovecii* if its Ct value is not defined in the results grid (the fluorescence curve does not cross the threshold line) on JOE/Yellow/HEX channel and in the results grid on FAM/Green channel the Ct value doesn't exceed H*.
- 3. The sample is considered to be invalid for *Pneumocystis jirovecii* if its Ct value is not defined in the results grid (the fluorescence curve does not cross the threshold line) on JOE/Yellow/HEX channel and in the results grid on FAM/Green channel the Ct value exceed H. PCR is to be repeated for this sample.



- 4. The sample is considered to be equivocal for *Pneumocystis jirovecii* if its Ct value exceed Z on JOE/Yellow/HEX channel. It is necessary to perform additional analysis in 2 repeats for this sample. If reproducible positive result is received, the sample is considered to be positive. If irreproducible result is received in 2 repeats, the sample is considered to be equivocal.
- 5. Negative result of analysis is considered to be unreliable if the Ct value exceed H on FAM/Green channel.
- * For X, Y, Z, H values see Guidelines [2].

Results are accepted as relevant if both positive and negative controls of amplification along with negative control of extraction are passed.

10. TROUBLESHOOTING


- If Ct value is present in Negative Control of extraction and Negative Control of Amplification on FAM/Green and JOE/Yellow/HEX channels in results grid, it indicates the contamination of reagent or samples. In such cases results of analysis must be considered as irrelevant. Test analysis must be repeated and measures to detect and eliminate the source of contamination are to be taken.
- If Ct values on FAM/Green channel (Glob) in studying blood or biopsy samples are higher than Ct values on FAM channel (Glob) in Positive Control of Amplification (Positive control DNA *P.jirovecii* and human DNA), it suggest about failures during extraction stage or insufficient amount of collected sample.
- If Ct value is absent in Positive Control of amplification on FAM/Green and/or JOE/Yellow/HEX channels, results of analysis for all samples are irrelevant. Analysis for all samples should be repeated starting from the PCR stage.

11. TRANSPORTATION

AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit should be transported at 2– 8 °C for no longer than 5 days.

12. STABILITY AND STORAGE

All components of the **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-FRT PCR kit (except for polymerase(TaqF) and PCR-mix-1-FRT *P.jirovecii /* Glob) are to be stored at 2–8 °C when not in use. All components of the **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-FRT PCR kit are to be stable until labeled expiration date. The shelf life of reagents before and after the first use is the same, unless otherwise stated.



Polymerase(TaqF) and PCR-mix-1-FRT *P.jirovecii* / Glob are to be stored at temperature from minus 24 to minus 16 °C when not in use.

PCR-mix-1-FRT *P.jirovecii* / Glob is to be kept away from light.

13. SPECIFICATIONS

13.1. Sensitivity

Analytical Sensitivity of **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-FRT PCR kit is no less than 500 copies per 1 ml of sample.



The claimed analytical features of **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-**FRT** PCR kit are guaranteed only when additional reagents kits DNA-sorb-B or RIBO-prep (manufactured by Federal Budget Institute of Science "Central Research Institute for Epidemiology") are used.

13.2. Specificity

Specificity of **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-FRT PCR kit is assured by selection of specific primers and probes, as well as the selection of strict reaction conditions. The primers and probes were checked for possible homologies to all in gene banks published sequences by sequence comparison analysis. Specificity of **AmpliSens[®]** *Pneumocystis jirovecii (carinii)*-FRT PCR kit was confirmed in laboratory clinical trials.

14. REFERENCES

- Handbook "Sampling, transportation, storage of clinical material for PCR diagnostics", developed by Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service for Surveillance on Consumers' Rights Protection and Human Well-Being, Moscow, 2008.
- 2. Guidelines to AmpliSens[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit for qualitative detection of *Pneumocystis jirovecii (carinii)* DNA in clinical material by using real-time hybridization-fluorescence detection developed by Federal Budget Institute of Science "Central Research Institute for Epidemiology".

15. QUALITY CONTROL

In compliance with Federal Budget Institute of Science "Central Research Institute for Epidemiology" ISO 13485-Certified Quality Management System, each lot of **AmpliSens**[®] *Pneumocystis jirovecii (carinii)*-FRT PCR kit has been tested against predetermined specifications to ensure consistent product quality.

16. KEY TO SYMBOLS USED

| REF | Catalogue number | \triangle | Caution |
|-----------|---|-------------|--------------------------------------|
| LOT | Batch code | Σ | Sufficient for |
| IVD | <i>In vitro</i> diagnostic medical device | \sum | Expiration Date |
| VER | Version | Ĭ | Consult instructions for use |
| | Temperature limitation | | Keep away from sunlight |
| | Manufacturer | NCA | Negative control of amplification |
| \sim | Date of manufacture | C- | Negative control of extraction |
| EC REP | Authorised representative in the European Community | C+ | Positive control of Amplification |
| FBIS CRIE | Federal Budget Institute of Science "Central Research Institute for Epidemiology" | IC | Internal control |



| VER | Location of changes | Essence of changes |
|----------------|--------------------------|--|
| | Cover page | The phrase "For Professional Use Only" was added |
| | Intended use | The phrase "The results of PCR analysis are taken into account in complex diagnostics of disease" was added. |
| | Content | New sections "Working Conditions" and "Transportation" were added |
| 27.12.10 RT | .12.10 | The "Explanation of Symbols" section was renamed to "Key to Symbols Used" |
| | Stability and Storage | The information about the shelf life of open reagents was added |
| | | Information that PCR-mix-1-FRT <i>P.jirovecii</i> / Glob is to be kept away from light was added |
| | Key to Symbols Used | The explanation of symbols was corrected |
| 30.06.11 LA | Cover page, text | The name of Institute was changed to Federal Budget Institute of Science "Central Research Institute for Epidemiology" |
| 20.01.13 LA | Text | Due to replacing appendix 1, 2, 3 with guidelines, references to appendixes were substitute by reference to guidelines |